Compare MBAI & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBAI | AIMD |
|---|---|---|
| Founded | 2004 | 1984 |
| Country | Israel | United States |
| Employees | 85 | 41 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 13.1M |
| IPO Year | N/A | N/A |
| Metric | MBAI | AIMD |
|---|---|---|
| Price | $1.38 | $1.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 102.5K | 23.6K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $0.44 |
| 52 Week High | $3.92 | $4.50 |
| Indicator | MBAI | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 53.17 |
| Support Level | $1.44 | $1.58 |
| Resistance Level | $1.83 | $1.75 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 23.95 | 46.51 |
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.